Kiora Pharmaceuticals, Inc. - Common Stock KPRX 深 沪
等待开盘 12-25 09:30:00 美东时间
2.05
-0.070
-3.30%
华盛通- 最 高2.11
- 今 开2.11
- 成交量 2.09万股
- 最 低 2.0001
- 昨 收 2.12
- 总市值 753.97万
- 52周最高 4.18
- 市盈率 静 2.35
- 换手率 0.57%
- 52周最低 1.7645
- 委 比 88.68%
- 总股本 367.79万
- 历史最高 189000.00
- 量 比 0.69
- 振 幅 5.18%
- 历史最低 1.7645
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kiora Pharmaceuticals Secures New US Patent to Expand Delivery Options for Eye Drug KIO-104
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent
12-01 20:11
Kiora Pharmaceuticals Reports Improved Financial Performance
Kiora Pharmaceuticals, Inc. ( ($KPRX) ) has released its Q3 earnings. Here is a...
11-11 12:30
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
11-07 19:11
Kiora Pharmaceuticals Joins Global Genes' RARE-X Vision Consortium, A Corporate-Nonprofit Initiative Aimed At Advancing Research For Rare Ocular Disorders
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate
10-30 21:07
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema?
Kiora Pharmaceuticals, Inc. (($KPRX)) announced an update on their ongoing clin...
10-28 03:28
Kiora Pharmaceuticals Files For $100M Mixed Shelf Offering
https://www.sec.gov/Archives/edgar/data/1372514/000137251425000072/s-3xseptember2025.htm
09-16 04:26
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $10 price target.
09-02 19:14
Kiora Pharmaceuticals GAAP EPS of -$0.54
Kiora Pharmaceuticals press release (NASDAQ:KPRX): Q2 GAAP EPS of -$0.54. Ended the quarter with $20.7 million in cash, cash equivalents and short-term investments, along with $2.4 million in collabor...
08-08 19:09
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection For KIO-104 In The Treatment of Ocular Disease
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases. This includes, but is not limited to,
07-22 21:09
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors
Kiora Pharmaceuticals ( ($KPRX) ) has issued an announcement. On June 4, 2025, ...
06-05 02:57
